LAS VEGAS — Patients with glaucoma showed high response rates after receiving a bimatoprost implant to reduce IOP, according to research presented at the American Society of Cataract and Refractive Surgery meeting.
E. Randy Craven, MD, said reliance on multiple topical medications remains an unmet need in the treatment of glaucoma.
“We all know that topical therapy kind of runs out of steam, if you will,” he said. “The bimatoprost implant was developed to try to help target that, giving patients therapy so we didn’t need to worry about non-usage.”
Researchers